Lantheus Holdings Inc
NASDAQ:LNTH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
W
|
Westrock Co
LSE:0LW9
|
US |
|
Nath Bio-Genes (I) Ltd
NSE:NATHBIOGEN
|
IN |
|
Z
|
Zhejiang Dayang Biotech Group Co Ltd
SZSE:003017
|
CN |
|
Neste Oyj
OMXH:NESTE
|
FI |
|
Jiangsu Yinhe Electronics Co Ltd
SZSE:002519
|
CN |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (11.9), the stock would be worth $67.12 (18% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 14.5 | $81.57 |
0%
|
| 3-Year Average | 11.9 | $67.12 |
-18%
|
| 5-Year Average | 14 | $79.16 |
-3%
|
| Industry Average | 12.9 | $72.7 |
-11%
|
| Country Average | 14.4 | $80.99 |
-1%
|
Forward EV/EBITDA
Today’s price vs future ebitda
| Today's Enterprise Value | EBITDA | Forward EV/EBITDA | ||
|---|---|---|---|---|
|
$5.1B
|
/ |
Jan 2026
$380.9m
|
= |
|
|
$5.1B
|
/ |
Dec 2026
$518.4m
|
= |
|
|
$5.1B
|
/ |
Dec 2027
$604.6m
|
= |
|
|
$5.1B
|
/ |
Dec 2028
$709.6m
|
= |
|
Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Lantheus Holdings Inc
NASDAQ:LNTH
|
5.3B USD | 14.5 | 22.6 | |
| US |
M
|
Medline Inc
NASDAQ:MDLN
|
62.4B USD | 0 | 0 | |
| JP |
|
Hoya Corp
TSE:7741
|
9.8T JPY | 28.4 | 39.1 | |
| CH |
|
Alcon AG
SIX:ALC
|
30.5B CHF | 14.9 | 38.9 | |
| DK |
|
Coloplast A/S
CSE:COLO B
|
98.2B DKK | 12.9 | 24.5 | |
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
13.9B USD | 14.8 | 34 | |
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
4.5B GBP | 11.9 | 34.2 | |
| CA |
|
Bausch + Lomb Corp
NYSE:BLCO
|
5.7B USD | 16.9 | -15.7 | |
| KR |
H
|
HLB Inc
KOSDAQ:028300
|
8.4T KRW | -83.8 | -37.5 | |
| JP |
A
|
Asahi Intecc Co Ltd
TSE:7747
|
895.2B JPY | 23.9 | 50.6 | |
| CN |
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
35.6B CNY | 19 | 21.3 |
Market Distribution
| Min | 0 |
| 30th Percentile | 10 |
| Median | 14.4 |
| 70th Percentile | 21.5 |
| Max | 1 767 274.1 |
Other Multiples
Lantheus Holdings Inc
Glance View
Lantheus Holdings Inc. is a captivating player in the healthcare sector, primarily operating within the niche of diagnostic medical imaging. The company's core mission revolves around enhancing diagnosis and treatment pathways, thus playing an integral role in patient care. At the heart of Lantheus's operations are its innovative diagnostic and therapeutic products, including radiopharmaceuticals and contrast agents that physicians rely on to obtain detailed images of the body's organs and tissues. Through a combination of proprietary technologies and strategic partnerships, Lantheus delivers solutions that help medical professionals make more informed clinical decisions, ultimately aiming to improve patient outcomes. This business generates revenue by developing, manufacturing, and commercializing its products, which are utilized across hospitals, clinics, and research centers worldwide. By consistently investing in research and development, Lantheus ensures a competitive edge through a robust pipeline of next-generation imaging agents. Strategic alliances and collaborative ventures further fortify its market presence, allowing the company to expand its reach and integrate new advancements into its product offerings. This commitment to innovation and collaboration has not only cemented its reputation in the life sciences industry but also ensures a steady and growing stream of income from its well-regarded product lines.
